• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Lilly Modifies Purchase Agreement with U.S. for COVID Therapies

    Sanofi Acquires Tidal Therapeutics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Digitalization and the Future of Formulating in Modern R&D Labs

    Sanofi Acquires Tidal Therapeutics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Alcami

    Aphena Pharma Solutions

    Reed-Lane

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Almac Group

    Baxter BioPharma Solutions

    Emergent BioSolutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Year-End Trends in Biopharma Contract Manufacturing

    Budgets are flattening, but some CMOs are well positioned for growth

    Year-End Trends in Biopharma Contract Manufacturing
    Year-End Trends in Biopharma Contract Manufacturing
    Related CONTENT
    • Vetio Animal Health
    • Current Trends in Analytical Testing
    • CMOs & Biosimilars Mfg. in the U.S.
    • CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    • Biopharmaceutical Contract Manufacturing
    Eric S. Langer, BioPlan Associates11.09.16
    Biopharmaceutical contract manufacturing has been on the upswing for several years now, with client budgets growing and contract manufacturing organizations (CMOs) anecdotally reporting increased business. Part of the reason for this movement has been a more strategic approach to outsourcing that has gone beyond basic cost calculations and benefited from CMOs’ leading-edge approach to innovation.

    Even so, 2016 has presented some new headwinds for outsourcing. Client budgets appear to be softening in favor of in-house strategies for some operations. The push toward more international outsourcing also seems to have stagnated to some degree. Below, we review some of the key outsourcing-related themes to emerge from our latest industry study, BioPlan Associates’ 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.1

    Is the budget boom over?
    In recent years, our study has demonstrated that outsourcing budgets have rebounded strongly. After small spending decreases in 2009, 2010 and 2012, respondents planned to increase their spending on outsourced biopharmaceutical manufacturing by 1.7% in 2013, 3.8% in 2014 and 3.7% in 2015.

    That enthusiasm appears to have come back down to earth. This year, respondents to our study forecast a modest 2.4% increase for outsourced biopharmaceutical manufacturing.
    While it’s true that these increases are compound from one year to the next—so presumably we won’t consistently see higher growth rates—this year’s more modest increase has taken place alongside a different trend: a jump in spending on in-house manufacturing.

    This year, biopharmaceutical manufacturers signaled that they would increase their spending on in-house manufacturing by 4.9%, about double the growth rate set for outsourced manufacturing.

    What this means is a potential return to the budget trends we saw from 2009 through 2013, when in-house manufacturing spending was growing at a faster rate than outsourced manufacturing spending. That trend reversed itself to the benefit of CMOs in 2014 and 2015, but it may be that those days were short-lived.
    The slowdown in budget growth comes at a time when respondents are reporting slightly lower levels of outsourcing than they did last year. Specifically:
    • For mammalian cell culture, 41% are keeping all of their manufacturing in-house this year, up from 35% doing so last year;
    • For microbial fermentation, close to half (45%) are not outsourcing any production, up from 39% last year; and
    • For yeast, plant and insect cells, while outsourcing is not common, it has become less so this year.
    Outsourcing budgets may be directed more towards R&D than manufacturing. Separately in our report we asked respondents to indicate how their spending on outsourcing will change over the coming 12 months for R&D, and for manufacturing. The estimated 14% increase came in above the 13% increases from the past couple of years, as well as the 10% projected increase from 2013.

    This potential trend could be the result of biosimilars bringing in new outsourcing players and new entrants based in Asia and other developing countries increasingly entering biopharmaceutical R&D. As biopharmaceuticals capture a larger share of the entire pharmaceutical drug pipeline—and with these biopharmaceuticals originating from more diverse sources—there may be greater occasion to outsource R&D activities to CMOs. Moreover, collaborations between large biopharmaceutical companies and local companies around the world often involve outsourcing of R&D and licensing of manufacturing rights. The use of CMOs can make product manufacturing—particularly for R&D—more efficient and often less costly. While globalization plans have taken a bit of a hit this year, we can expect more use of developing country-based CROs and CMOs, primarily to support pre-commercial R&D.

    Another possible explanation for the slowdown in outsourced manufacturing budget growth this year is that companies are beginning to look more again at outsourcing specifically as a cost-cutting mechanism, wanting to squeeze more out of their existing budgets.

    To that end, we note that 18% of respondents this year offshored manufacturing specifically in order to cut costs, with that figure almost double the share from 2012 (9.4%) and more than triple the share from 2011 (5.7%). Likewise, around 1 in 6 (16.7%) outsourced manufacturing to domestic service providers to cut costs, more than double the proportion from 2011 (7.1%). If outsourcing is going to be seen primarily as a way to cut costs, it’s unlikely that budgets will have the same buoyancy seen in recent years.

    CMOs’ innovation focus continues
    A key benefit provided by CMOs that has enabled them to move past simple cost considerations is their leading edge adoption of new technologies, particularly in areas such as single use applications. Whereas biotherapeutic developers are often tied to existing expensive platform processes, CMOs are expected to be more agile, as they have to work with several different client projects at the same time. This agility necessitates less reliance on established processes, which in turn allows CMOs to adopt newer technologies at a faster rate than biotherapeutic developers.

    This pattern continues to be seen this year in our research. In terms of disposables, for example, we have found that CMOs are outpacing biotherapeutic developers in 15 of the 16 applications we tested for adoption. Perfusion devices are the only ones adopted by slightly more biotherapeutic developers than CMOs. Some of the biggest differences in adoption relate to:
    • Tangential flow filtration devices, used by 93% of CMOs and 68% of developers; and
    • Membrane adsorbers, used by two-thirds of CMOs as opposed to 4 in 10 developers.
    Single-use applications’ appeal to CMOs is also evidenced when looking at their new product development areas of interest. Disposable purification products emerge as the leading area in which they want suppliers to focus their development efforts, while for biotherapeutic developers, continuous downstream bioprocessing is the top area of interest.

    Not surprisingly, these top areas of interest relate to downstream purification. Our study indicates that CMOs are also embracing several new downstream purification technologies at a greater rate than biotherapeutic developers—although the tilt isn’t quite as heavy compared with single-use systems, many novel downstream applications are still in early commercialization stages. Some of the downstream technologies being considered by CMOs to a larger degree than biotherapeutic developers this year include the use of high-capacity resins, in-line buffer dilution systems, single-use disposable TFF membranes, disposable UF systems and the use of filters instead of resin chromatography.

    Demand for additional testing services an area of opportunity
    The majority of the outsourcing activities that we tested for current usage have remained relatively flat from last year, according to our report. This is true for heavily-outsourced activities such as fill-finish operations—74% outsourcing to at least some degree this year, compared to 73% last year—and those lower on the adoption scale, such as upstream process development—42% this year, compared to 43% last year.

    So it’s interesting to see that the biggest year-over-year swings in adoption have been observed for testing services. There have been increases in adoption of roughly five percentage points or more for analytical testing of bioassays, toxicity testing, cell line stability testing, and host cell protein analysis testing. The last of these—host cell protein analysis testing—saw the biggest shift from last year, with 56% reporting outsourcing this activity to some degree, up from 42%.

    To be fair, some other more routine testing services haven’t seen the same increases: the percentages outsourcing lot release testing, for example, is relatively stable from last year.

    Globalization push stagnates
    While we noted earlier that new entrants in Asian and other emerging economies could have an impact on outsourcing spending on R&D as opposed to manufacturing, our study at the same time finds that offshoring plans have muted somewhat from recent years.

    Although more biopharmaceutical manufacturers this year report having offshored manufacturing specifically in order to cut costs, offshoring projections for the future have tempered relative to a couple of years ago.

    Specifically, this year about one-third (35%) of biomanufacturers say they expect to offshore at least some process development activities in the next 5 years. This is well below the levels seen in 2011, 2012 and 2014, which ranged between 43% and 46% of respondents.

    Likewise, the 43% of respondents expecting to outsource biomanufacturing operations in the coming 5 years is unchanged from last year and down from 47% in 2014. And the 57% predicting that they’ll offshore at least some clinical trials/operations by 2021 is squarely in the 56%-58% range from the 3 prior years.

    When we averaged the data among all respondents, we found that the average percentage of operations to be offshored in the next 5 years is either trending down or flat from prior years:
    • Process development for biomanufacturing: 3.9% of all operations to be offshored, down from 4.4% last year and a high of 8.8% in 2012;
    • Clinical trials/operations: 10.2% to be offshored, in line with the previous 2 years and down from a high of 12.2% in 2011; and
    • Biomanufacturing operations: 9.4% to be offshored, down from 11.3% in 2014 and 11.9% in 2011.
    Looking forward
    Results from this year’s study are interesting in that they present a deviation from some established trends we’ve observed in recent years. Namely, that budgets aren’t going to keep expanding indefinitely and that globalization might be a little bit bumpier than we might have previously envisioned. Still, we continue to see consistency in CMOs’ willingness to trial and adopt new technologies, most commonly in single-use systems and downstream processing.

    With the advent of biosimilars, we could expect that next year our study will show a renewed focus on globalization. Spending on outsourced manufacturing will also likely increase again, though perhaps not to the same degree seen in prior years. Stay tuned to see how these developments play out. 

    References
    1. 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, Inc. Rockville, MD., April 2016

    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com;  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Biopharmaceutical Contract Manufacturing Biopharmaceutical Contract Manufacturing
    Economics of In-House  Buffer Preparation Economics of In-House Buffer Preparation
    Contract Manufacturing Budget Trends Contract Manufacturing Budget Trends
    China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects
    Biopharmaceutical Contract Manufacturing Contract Negotiations Biopharmaceutical Contract Manufacturing Contract Negotiations
    Taking Stock of Biopharma’s Outsourcing Markets Taking Stock of Biopharma’s Outsourcing Markets
    Globalization Hits Biopharma Contract Manufacturing Globalization Hits Biopharma Contract Manufacturing
    CMOs Are Willing to Pay for More Innovation CMOs Are Willing to Pay for More Innovation
    Top 15 Trends in Biopharmaceutical Manufacturing Top 15 Trends in Biopharmaceutical Manufacturing
    BioPlan Associates Publishes Latest Report BioPlan Associates Publishes Latest Report
    Getting to Yes Getting to Yes

    Related Columns

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      What Will Change at FDA for 2021?

      What Will Change at FDA for 2021?

      (R)evolution of the industry’s data, catalyzed by changes at FDA and what’s the likely impact to the pharmaceutical industry?
      Ben Locwin, Contributing Editor, International COVID-19 Advisor, Healthcare Futurist 04.01.21

    • Biologics, Proteins, Vaccines
      Vaccines and Return-To-Normalcy

      Vaccines and Return-To-Normalcy

      Planning for a future in which COVID-19 won’t simply ‘disappear.’
      Ben Locwin, Contributing Editor 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21


    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      Outsourcing in China: How far can it go?

      Outsourcing in China: How far can it go?

      China’s biopharmaceutical services market is on pace to top $1 billion by 2021
      Vicky Qing Xia, BioPlan Associates 07.15.19

    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19


    • Biologics, Proteins, Vaccines
      Innovate UK Grant Supports Viral Vector Manufacturing

      Innovate UK Grant Supports Viral Vector Manufacturing

      Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment
      Betsy Louda, Associate Editor 04.10.18

    • Biologics, Proteins, Vaccines | Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17

    • Biologics, Proteins, Vaccines
      India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17


    • Biologics, Proteins, Vaccines
      Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Trends in New Technologies & Budgets

      Trends in New Technologies & Budgets

      Budget increases in biopharmaceutical industry indicate future growth
      Eric S. Langer, BioPlan Associates 06.06.17

    • Biologics, Proteins, Vaccines

      Biomanufacturing Trends and Outlook 2017: Where Is It All Going?

      A look at the technological advances permeating (bio)pharma manufacturing
      Ben Locwin, Contributing Editor 04.20.17


    • Biologics, Proteins, Vaccines
      CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges

      CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

      Technically trained staff needed to run complex manufacturing platforms, automation
      Eric S. Langer, BioPlan Associates 03.07.17

    • Biologics, Proteins, Vaccines

      Economics of In-House Buffer Preparation

      Evaluating the cost effectiveness of keeping basic ops in-house
      Eric S. Langer, BioPlan Associates 09.08.16

    • Biologics, Proteins, Vaccines | cGMP Manufacture | GMPs/GCPs | Preclinical Outsourcing | Process Development | Risk Management

      Getting to Yes

      The critical attributes CMOs need to demonstrate to win business
      Eric S. Langer, BioPlan Associates 07.14.15

    Trending
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • ANI Acquires Branded Products Portfolio From Sandoz
    • FDA Accepts Airway Therapeutics’ IND For COVID Treatment
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    Breaking News
    • Lonza Expands PyroTec PRO for Endotoxin Testing
    • FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    • Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    • Lilly Modifies Purchase Agreement with U.S. for COVID Therapies
    • Sanofi Acquires Tidal Therapeutics
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    KD Pharma Acquires Rohner AG Manufacturing Assets
    Thorne Healthtech and PreCon Health to Launch Supplements for Pre-, Post-Impact Brain Health
    Green Leafy Vegetable Intervention Reduces Marker of Colorectal Cancer Risk, Study Finds
    Coatings World

    Latest Breaking News From Coatings World

    BCF's Tom Bowtell Voted VP of World Coatings Council
    Chromaflo Technologies to Sponsor, Exhibit at North American Pultrusion Conference 2021
    EU Innovation Fund Evaluating Perstorp-created Project AIR
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Avantor to Acquire Ritter GmbH and Affiliates for $1B
    ZOLL Buys Sleep Apnea Device Maker Respicardia
    Digital Diabetes Management Market Projected to Reach $54 Billion by 2027
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Lonza Expands PyroTec PRO for Endotoxin Testing
    FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Honest Co. Files for an Initial Public Offering
    China Builds ‘Beauty and Healthcare Industrial Park’ in Guangzhou
    Edition Spéciale by Luxe Pack is Postponed
    Happi

    Latest Breaking News From Happi

    OTC Pain Relief QR Cream Debuts in US Market
    Professional Beauty Association Opens Registration for Summit
    Makeup Leader Laura Geller Teams Up with Actress Fran Drescher
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mark Andy launches monochrome digital print bar
    Label Traxx launches Siteline online artwork approvals system
    Kocher + Beck appoints new regional sales manager
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    NXTNano Adding Three Lines
    Honest Company Plans IPO
    Asia Wipes Summit Held Successfully in Shanghai
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    SynerFuse, Cirtec Medical Partner to Develop Back Pain Management Device
    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    NREL: 10 Teams Emerge Victorious in Round 4 of American-Made Solar Prize
    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login